PDCD1 and lung carcinoma: Compared with chemotherapy, there was no OS advantage with PD-1/PD-L1 immune checkpoint inhibitors alone in lung cancer BMs (HR = 0.81, 95%CI = 0.57–1.05) (Figure 7).